Chemotherapy of advanced small-bowel adenocarcinoma: A multicenter AGEO study

Annals of Oncology

Volumn 21, Issue 9, 2010, Pages 1786-1793

  Zaanan, A ^a   Costes, L ^b   Gauthier, M ^c   Malka, D ^b   Locher, C ^d   Mitry, E ^e   Tougeron, D ^f   Lecomte, T ^g   Gornet, J M ^h   Sobhani, I ⁱ   Moulin, V ^j   Afchain, P ^a   Taieb J ^k   Bonnetain, F ^c   Aparicio, T ^l,m  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c Biostatistic and Quality of Life Unit Georges François Leclerc Center   (France)

^d Emergency Department Smur 77   (France)

^e HÔPITAL AMBROISE PARÉ   (France)

^f HÔPITAL CHARLES NICOLLE   (France)

^g UNIVERSITÉ DE TOURS   (France)

^h SAINT LOUIS HOSPITAL   (France)

ⁱ HENRI MONDOR HOSPITAL   (France)

^j Louis Pasteur Hospital   (France)

^k ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^l AVICENNE HOSPITAL   (France)

^m AGEO (Association des Gastroente'rologues Oncologues/Gastroenterologists Oncologists Association)   (France)

more..

Author keywords

Chemotherapy; Prognostic factor; Small bowel adenocarcinoma

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CISPLATIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SMALL INTESTINE ADENOCARCINOMA; SMALL INTESTINE CARCINOMA; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

EID: 77956124154     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq038     Document Type: Article

References (34)

1. Neugut AI, Marvin MR, Rella VA, Chabot JA. An overview of adenocarcinoma of the small intestine. Oncology (Williston Park) 1997; 11: 529-536.
2. Stang A, Stegmaier C, Eisinger B et al. Descriptive epidemiology of small intestinal malignancies: the German Cancer Registry experience. Br J Cancer 1999; 80: 1440-1444.
3. Chow JS, Chen CC, Ahsan H, Neugut AI. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol 1996; 25: 722-728.
4. Hatzaras I, Palesty JA, Abir F et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut tumor registry. Arch Surg 2007; 142: 229-235.
5. Green PH, Jabri B. Celiac disease and other precursors to small-bowel malignancy. Gastroenterol Clin North Am 2002; 31: 625-639.
6. Howe JR, Karnell LH, Menck HR, Scott-Conner C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer 1999; 86: 2693-2706.
7. Dabaja BS, Suki D, Pro B et al. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer 2004; 101: 518-526.
8. Talamonti MS, Goetz LH, Rao S, Joehl RJ. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg 2002; 137: 564-570.
9. Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol) 2007; 19: 143-149.
10. Fishman PN, Pond GR, Moore MJ et al. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am J Clin Oncol 2006; 29: 225-231.
11. Crawley C, Ross P, Norman A et al. The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer 1998; 78: 508-510.
12. Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist 2005; 10: 132-137.
13. Jigyasu D, Bedikian AY, Stroehlein JR. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 1984; 53: 23-25.
14. Locher C, Malka D, Boige V et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology 2005; 69: 290-294.
15. Overman MJ, Kopetz S, Wen S et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer 2008; 113: 2038-2045.
16. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7: 573-584.
17. Levi F, Perpoint B, Garufi C et al. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993; 29A: 1280-1284.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
19. de Gramont A, Bosset JF, Milan C et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815.
20. Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 1041-1047.
21. Mitry E, Taieb J, Artru P et al. Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Ann Oncol 2004; 15: 765-769.
22. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18: 2938-2947.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958; 53: 457-481.
24. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163-170.
25. Cox D. Regression models and life-tables. J R Stat Soc 1972; B34: 187-202.
26. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340-349.
27. Overman MJ, Varadhachary GR, Kopetz S et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol 2009; 27: 2598-2603.
28. Kemeny N, Israel K, Niedzwiecki D et al. Randomized study of continuous infusion fluorouracil versus fluorouracil plus cisplatin in patients with metastatic colorectal cancer. J Clin Oncol 1990; 8: 313-318.
29. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358: 36-46.
30. Webb A, Cunningham D, Scarffe JH et al. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267.
31. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
32. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
33. Lievre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26: 374-379.
34. Nishiyama K, Yao T, Yonemasu H et al. Overexpression of p53 protein and point mutation of K-ras genes in primary carcinoma of the small intestine. Oncol Rep 2002; 9: 293-300.